Exane Asset Management Biogen Inc. Transaction History

Exane Asset Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 16, 2018	SELL	$293.51 - $383.83 $11.9 Million - $15.6 Million	-40,708 Closed	0 $0
Q2 2018 Sep 06, 2018	BUY	$257.52 - $306.91 $608,519 - $725,228	2,363 Added 6.16%	40,708 $0
Q1 2018 Apr 30, 2018	SELL	$260.13 - $367.91 $9.9 Million - $14 Million	-38,051 Reduced 49.81%	38,345 $0
Q4 2017 Feb 08, 2018	BUY	$307.64 - $344.58 $445,462 - $498,951	1,448 Added 1.93%	76,396 $0
Q3 2017 Oct 13, 2017	BUY	$281.15 - $329.69 $21.1 Million - $24.7 Million	74,948	74,948 $23.5 Billion

1,047

126M

1.37M

1.35M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $33B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Exane Asset Management, based on Form 13F filings with the SEC.

Stay updated on Exane Asset Management with notifications on news.